CRDF · Cardiff Oncology, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $593.0K | $683.0K | $488.0K | $386.0K | $366.0K | $366.0K |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $35.33M | $36.85M | $32.86M | $27.10M | $17.40M | $11.24M |
| SG&A | $14.22M | $12.48M | $13.04M | $13.18M | $11.84M | $8.22M |
| Total Operating Expenses | $49.55M | $49.33M | $45.90M | $40.29M | $29.21M | $19.45M |
| D&A | $364.0K | $404.0K | $398.0K | $236.0K | $451.0K | $466.0K |
| Operating Income | ($48.96M) | ($48.65M) | ($45.41M) | ($39.90M) | ($28.86M) | ($19.09M) |
| Interest Expense | - | - | - | - | $0 | $1.5K |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | ($45.85M) | ($45.43M) | ($41.44M) | ($38.70M) | ($28.29M) | ($19.31M) |
| EPS - Basic | ($0.69) | ($0.95) | ($0.93) | ($0.89) | ($1.08) | - |
| EPS - Diluted | ($0.69) | ($0.95) | ($0.93) | ($0.89) | ($1.08) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $17.47M | $51.47M | $21.66M | $16.35M | $11.94M | $130.98M |
| Accounts Receivable | $182.0K | $773.0K | $288.0K | $771.0K | $535.0K | $320.5K |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $8.09M | $4.82M | $1.97M | $1.96M | $1.44M | $1.37M |
| Current Assets | $60.13M | $95.05M | $77.41M | $111.28M | $146.13M | $133.36M |
| Total Assets | $61.88M | $97.19M | $81.64M | $116.19M | $149.54M | $134.73M |
| Current Liabilities | $16.39M | $13.43M | $10.44M | $7.81M | $6.56M | $6.12M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $16.50M | $14.24M | $11.90M | $9.85M | $9.13M | $6.57M |
| Stockholders' Equity | $45.39M | $82.95M | $69.74M | $106.34M | $140.42M | $128.16M |
| Retained Earnings | ($430.03M) | ($384.18M) | ($339.54M) | ($298.10M) | ($259.81M) | ($231.50M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($37.92M) | ($37.69M) | ($30.89M) | ($33.82M) | ($23.04M) | ($16.31M) |
| Investing Cash Flow | $1.34M | $13.73M | $36.20M | $38.15M | ($131.45M) | ($211.9K) |
| Financing Cash Flow | $2.58M | $53.78M | $0 | $75.0K | $35.45M | $137.31M |
| CapEx | $44.0K | $80.0K | $582.0K | $1.01M | $205.0K | $211.9K |
| Free Cash Flow | ($37.97M) | ($37.77M) | ($31.47M) | ($34.83M) | ($23.25M) | ($16.53M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | -8256.3% | -7123.1% | -9305.7% | -10337.3% | -7883.9% | -5214.8% |
| EBITDA margin | -8194.9% | -7064.0% | -9224.2% | -10276.2% | -7760.7% | -5087.5% |
| Net margin | -7732.0% | -6651.7% | -8492.0% | -10026.9% | -7729.8% | -5275.1% |
| Free cash flow margin | -6402.5% | -5530.5% | -6448.6% | -9022.3% | -6351.1% | -4515.6% |
| FCF / Net income | 0.83 | 0.83 | 0.76 | 0.90 | 0.82 | 0.86 |
| R&D / Revenue | 5957.7% | 5395.6% | 6733.0% | 7020.7% | 4754.1% | 3069.8% |
| SG&A / Revenue | 2398.7% | 1827.5% | 2672.7% | 3414.8% | 3234.4% | 2245.0% |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -74.1% | -46.7% | -50.8% | -33.3% | -18.9% | -14.3% |
| Return on equity | -101.0% | -54.8% | -59.4% | -36.4% | -20.1% | -15.1% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 3.67 | 7.08 | 7.41 | 14.25 | 22.28 | 21.79 |
| Quick ratio | 3.67 | 7.08 | 7.41 | 14.25 | 22.28 | 21.79 |
| Cash ratio | 1.07 | 3.83 | 2.07 | 2.09 | 1.82 | 21.41 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | -12564.8x |
| Equity multiplier | 1.36 | 1.17 | 1.17 | 1.09 | 1.06 | 1.05 |
| Liabilities / Assets | 0.27 | 0.15 | 0.15 | 0.08 | 0.06 | 0.05 |
| Efficiency | ||||||
| Asset turnover | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | 112d | 413d | 215d | 729d | 534d | 320d |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 4.1x | 2.5x | 0.9x | 0.6x | 0.9x | - |
| P / S | 316.7x | 302.8x | 135.5x | 158.1x | 342.8x | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | -13.2% | 40.0% | 26.4% | 5.5% | 0.0% | -3.3% |
| Revenue CAGR (3y) | 15.4% | 23.1% | 10.1% | 0.7% | -1.1% | -10.2% |
| Revenue CAGR (5y) | 10.1% | 12.5% | 5.2% | -5.2% | -0.8% | 3.2% |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | -0.6% | -7.1% | -13.8% | -38.3% | -51.2% | -14.4% |
| Net income growth (YoY) | -0.9% | -9.6% | -7.1% | -36.8% | -46.5% | -17.6% |
| EPS growth (YoY) | 27.4% | -2.2% | -4.5% | 17.6% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | -0.5% | -20.0% | 9.6% | -49.8% | -40.6% | -23.9% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -45.3% | 18.9% | -34.4% | -24.3% | 9.6% | 1652.9% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2020-12-31.
Product / service
$366.0K totalRoyalty$366.0K · 100.0%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
-6.67
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Cardiff Oncology against the 5 most active filers in the same SIC group.